Doxorubicin inactivates the EGFR/Src/HMG-CR pathway, and decreases levels of both cholesterol and lipid rafts. Simvastatin enhances doxorubicin-induced cell death but cholesterol attenuates it. The anti-cancer effect of doxorubicin is attenuated in cholesterol-high diet-fed mice. Therefore, cholesterol control may be combined with treatment to enhance doxorubicin efficacy and reduce its side effects.
- Un-Jung Yun
- Ji-Hye Lee
- Yong-Nyun Kim
